WO2013024589A1 - 敗血症の予防剤及び/又は治療剤 - Google Patents
敗血症の予防剤及び/又は治療剤 Download PDFInfo
- Publication number
- WO2013024589A1 WO2013024589A1 PCT/JP2012/005125 JP2012005125W WO2013024589A1 WO 2013024589 A1 WO2013024589 A1 WO 2013024589A1 JP 2012005125 W JP2012005125 W JP 2012005125W WO 2013024589 A1 WO2013024589 A1 WO 2013024589A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron
- sepsis
- compound
- group
- prophylactic
- Prior art date
Links
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 117
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 68
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 47
- 230000000069 prophylactic effect Effects 0.000 title claims abstract description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 66
- 229910052751 metal Inorganic materials 0.000 claims abstract description 44
- 239000002184 metal Substances 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 29
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 66
- 150000002506 iron compounds Chemical class 0.000 claims description 34
- 229910052742 iron Inorganic materials 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 230000003449 preventive effect Effects 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
- 108090001007 Interleukin-8 Proteins 0.000 claims description 7
- 150000002681 magnesium compounds Chemical class 0.000 claims description 7
- 150000003752 zinc compounds Chemical class 0.000 claims description 7
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 6
- KXFFQVUPQCREHA-UHFFFAOYSA-K sodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KXFFQVUPQCREHA-UHFFFAOYSA-K 0.000 claims description 6
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 claims description 5
- 239000005749 Copper compound Substances 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 102000008857 Ferritin Human genes 0.000 claims description 5
- 108050000784 Ferritin Proteins 0.000 claims description 5
- 238000008416 Ferritin Methods 0.000 claims description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 5
- 102000010445 Lactoferrin Human genes 0.000 claims description 5
- 108010063045 Lactoferrin Proteins 0.000 claims description 5
- 102000004338 Transferrin Human genes 0.000 claims description 5
- 108090000901 Transferrin Proteins 0.000 claims description 5
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 claims description 5
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 claims description 5
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 claims description 5
- 150000001845 chromium compounds Chemical class 0.000 claims description 5
- 150000001869 cobalt compounds Chemical class 0.000 claims description 5
- 150000001880 copper compounds Chemical class 0.000 claims description 5
- VEPSWGHMGZQCIN-UHFFFAOYSA-H ferric oxalate Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O VEPSWGHMGZQCIN-UHFFFAOYSA-H 0.000 claims description 5
- 239000004222 ferrous gluconate Substances 0.000 claims description 5
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 5
- 229960001645 ferrous gluconate Drugs 0.000 claims description 5
- 229960001604 ferrous succinate Drugs 0.000 claims description 5
- 150000003278 haem Chemical class 0.000 claims description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 5
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 5
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 claims description 5
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 5
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 5
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 claims description 5
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 5
- 229940078795 lactoferrin Drugs 0.000 claims description 5
- 235000021242 lactoferrin Nutrition 0.000 claims description 5
- 239000005078 molybdenum compound Substances 0.000 claims description 5
- 150000002752 molybdenum compounds Chemical class 0.000 claims description 5
- 150000002816 nickel compounds Chemical class 0.000 claims description 5
- 239000012581 transferrin Substances 0.000 claims description 5
- 150000003682 vanadium compounds Chemical class 0.000 claims description 5
- 239000011706 ferric diphosphate Substances 0.000 claims description 4
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 4
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 4
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 4
- 239000011640 ferrous citrate Substances 0.000 claims description 4
- 235000019850 ferrous citrate Nutrition 0.000 claims description 4
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 claims description 4
- BKJXSPNFVILSSW-UHFFFAOYSA-N n'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine;iron Chemical compound [Fe].NCCNCCNCCN BKJXSPNFVILSSW-UHFFFAOYSA-N 0.000 claims description 4
- LQPLDXQVILYOOL-UHFFFAOYSA-I pentasodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O LQPLDXQVILYOOL-UHFFFAOYSA-I 0.000 claims description 4
- LPOSZYSKJWFIQH-UHFFFAOYSA-N 2-aminoacetic acid;iron Chemical compound [Fe].NCC(O)=O LPOSZYSKJWFIQH-UHFFFAOYSA-N 0.000 claims description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 3
- VAGGJWZQGWBRPQ-QTNFYWBSSA-K [Na+].[Fe+2].C(=O)([O-])C(C(=O)[O-])N[C@@H](CCC(=O)O)C(=O)[O-] Chemical compound [Na+].[Fe+2].C(=O)([O-])C(C(=O)[O-])N[C@@H](CCC(=O)O)C(=O)[O-] VAGGJWZQGWBRPQ-QTNFYWBSSA-K 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- OOTLZFANIDERRE-UHFFFAOYSA-K sodium butanedioic acid 2-hydroxypropane-1,2,3-tricarboxylate iron(2+) Chemical compound [Na+].[Fe+2].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].C(CCC(=O)O)(=O)O OOTLZFANIDERRE-UHFFFAOYSA-K 0.000 claims description 2
- SRFKWQSWMOPVQK-UHFFFAOYSA-K sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate;iron(2+) Chemical compound [Na+].[Fe+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SRFKWQSWMOPVQK-UHFFFAOYSA-K 0.000 claims description 2
- ZQYIIXDVDFBWPZ-QTNFYWBSSA-M [NH4+].[Fe+].OC(=O)C(C(O)=O)N[C@H](C([O-])=O)CCC([O-])=O Chemical compound [NH4+].[Fe+].OC(=O)C(C(O)=O)N[C@H](C([O-])=O)CCC([O-])=O ZQYIIXDVDFBWPZ-QTNFYWBSSA-M 0.000 claims 1
- XNSQZBOCSSMHSZ-UHFFFAOYSA-K azane;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate;iron(3+) Chemical compound [NH4+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O XNSQZBOCSSMHSZ-UHFFFAOYSA-K 0.000 claims 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 claims 1
- 235000003891 ferrous sulphate Nutrition 0.000 claims 1
- 239000011790 ferrous sulphate Substances 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 abstract description 27
- 229960002749 aminolevulinic acid Drugs 0.000 abstract description 25
- 239000004480 active ingredient Substances 0.000 abstract description 9
- 229910019142 PO4 Inorganic materials 0.000 abstract description 3
- 235000021317 phosphate Nutrition 0.000 abstract description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 2
- 150000002148 esters Chemical class 0.000 abstract description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 2
- 150000003840 hydrochlorides Chemical class 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 abstract description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 1
- -1 sodium ammonium dicarboxymethylglutamate Chemical compound 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 238000002428 photodynamic therapy Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 206010050685 Cytokine storm Diseases 0.000 description 9
- 206010052015 cytokine release syndrome Diseases 0.000 description 9
- 230000021995 interleukin-8 production Effects 0.000 description 7
- 210000001147 pulmonary artery Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 125000004494 ethyl ester group Chemical group 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000017306 interleukin-6 production Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 4
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000011773 ferrous fumarate Substances 0.000 description 4
- 235000002332 ferrous fumarate Nutrition 0.000 description 4
- 229960000225 ferrous fumarate Drugs 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910000358 iron sulfate Inorganic materials 0.000 description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229950003776 protoporphyrin Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 241000024188 Andala Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- ZLHFONARZHCSET-UHFFFAOYSA-N 5-aminolevulinic acid hydrochloride Chemical compound Cl.NCC(=O)CCC(O)=O ZLHFONARZHCSET-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- UFNDVKMTMUMBSU-UHFFFAOYSA-N [Fe]=S.NCC(=O)O Chemical compound [Fe]=S.NCC(=O)O UFNDVKMTMUMBSU-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FJZZHNSAKKNYJJ-QTNFYWBSSA-N diazanium;(2s)-2-(dicarboxymethylamino)pentanedioate Chemical compound [NH4+].[NH4+].OC(=O)C(C(O)=O)N[C@H](C([O-])=O)CCC([O-])=O FJZZHNSAKKNYJJ-QTNFYWBSSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical class CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LKZLBQPNDYMRJE-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron;sodium Chemical compound [Na].[Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LKZLBQPNDYMRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 101710084741 5-aminolevulinate synthase Proteins 0.000 description 1
- 101710188223 5-aminolevulinate synthase, mitochondrial Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- HNBPGMZUKDCQEE-UWTATZPHSA-N D-alanyl phosphate Chemical compound C[C@@H](N)C(=O)OP(O)(O)=O HNBPGMZUKDCQEE-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- BJOACXCMRJVHAK-LHWPGRLPSA-L N[C@@H](CCC(=O)[O-])C(=O)[O-].[Fe+2].C(=O)(O)C(C(=O)O)[Na] Chemical compound N[C@@H](CCC(=O)[O-])C(=O)[O-].[Fe+2].C(=O)(O)C(C(=O)O)[Na] BJOACXCMRJVHAK-LHWPGRLPSA-L 0.000 description 1
- JECNXYCEUGJQKQ-LHWPGRLPSA-K N[C@@H](CCC([O-])=O)C([O-])=O.[O-]C(C(C(O)=O)[Fe+])=O.[Fe+2] Chemical compound N[C@@H](CCC([O-])=O)C([O-])=O.[O-]C(C(C(O)=O)[Fe+])=O.[Fe+2] JECNXYCEUGJQKQ-LHWPGRLPSA-K 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- DYPHJEMAXTWPFB-UHFFFAOYSA-N [K].[Fe] Chemical compound [K].[Fe] DYPHJEMAXTWPFB-UHFFFAOYSA-N 0.000 description 1
- MVXPPHMUGOVFBT-UHFFFAOYSA-L [NH4+].C(C)(=O)[O-].C(C)(=O)O.C(C)(=O)O.C(C)(=O)[O-].C(C)(=O)[O-].[Mg+2].NCCNCCN Chemical compound [NH4+].C(C)(=O)[O-].C(C)(=O)O.C(C)(=O)O.C(C)(=O)[O-].C(C)(=O)[O-].[Mg+2].NCCNCCN MVXPPHMUGOVFBT-UHFFFAOYSA-L 0.000 description 1
- XKPMDXAYDXOODD-UHFFFAOYSA-N [Na].[Na].[Mg].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O Chemical compound [Na].[Na].[Mg].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XKPMDXAYDXOODD-UHFFFAOYSA-N 0.000 description 1
- XUKAFOLYJQTZHL-UHFFFAOYSA-N [Na].[Na].[Zn].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O Chemical compound [Na].[Na].[Zn].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XUKAFOLYJQTZHL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- PJAOJNOBFQOBGE-UHFFFAOYSA-L azanium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate;iron(2+) Chemical compound [NH4+].[Fe+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O PJAOJNOBFQOBGE-UHFFFAOYSA-L 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- ZNRVBINYQYCPPK-QTNFYWBSSA-L disodium (2S)-2-(dicarboxymethylamino)pentanedioate Chemical compound [Na+].[Na+].OC(=O)C(C(O)=O)N[C@H](C([O-])=O)CCC([O-])=O ZNRVBINYQYCPPK-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- PJJZFXPJNUVBMR-UHFFFAOYSA-L magnesium benzoate Chemical compound [Mg+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 PJJZFXPJNUVBMR-UHFFFAOYSA-L 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WRNAXXCYSNLIJM-UHFFFAOYSA-K sodium 2-hydroxypropane-1,2,3-tricarboxylate 2-hydroxypropane-1,2,3-tricarboxylic acid iron(2+) Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)O.[Fe+2] WRNAXXCYSNLIJM-UHFFFAOYSA-K 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- UDJMEHOEDIAPCK-UHFFFAOYSA-N sodium iron(2+) oxygen(2-) Chemical compound [O-2].[Fe+2].[Na+] UDJMEHOEDIAPCK-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LESFYQKBUCDEQP-UHFFFAOYSA-N tetraazanium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound N.N.N.N.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LESFYQKBUCDEQP-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- YUMLNTJCWGYGQU-UHFFFAOYSA-N zinc azane Chemical compound N.N.[Zn+2] YUMLNTJCWGYGQU-UHFFFAOYSA-N 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a prophylactic and / or therapeutic agent for sepsis, and more particularly, to prevention of sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt thereof as an active ingredient.
- the present invention relates to an agent and / or a therapeutic agent.
- Sepsis is positioned as systemic response syndrome (SIRS) caused by bacterial infections such as wounds, puerperium, and diseases.
- SIRS systemic response syndrome
- the main body of SIRS is hypercytokinemia.
- the cytokine is an inflammatory substance and the toxin produced by the infected bacteria causes blood vessels to dilate and blood pressure to decrease. If the blood pressure lowers significantly, the blood flow in each part of the body is insufficient and the risk of malfunctioning of each organ increases.
- the heart increases its heart rate to increase blood flow, but overload reduces cardiac function, chronically lacks blood supply to important organs, and septic shock It leads to "multi-organ failure".
- PDT therapy photodynamic therapy
- PDT treatment is a treatment method that combines a photosensitizer and light irradiation.
- 5-ALA itself does not have photosensitization, it is metabolized in the body to become the photosensitizer protoporphyrin IX (PPIX), and is therefore used for PDT treatment of cancer (for example, Patent Documents 1 to 3). reference).
- PDT treatment for example, Patent Documents 1 to 3). reference.
- Clinical cases have already been reported on PDT therapy for acne vulgaris using 5-ALA, and it has shown remarkable effects. (For example, refer nonpatent literature 1).
- PDT treatment has indeed shown an effect on bacterial infections on the skin, but in order to kill bacteria in the blood, such as sepsis, a light source must be irradiated directly into the blood.
- the absorption wavelength suitable for the excitation of PPIX overlaps with the absorption spectrum of hemoglobin, and it is necessary to insert an excitation light source into the blood vessel via a catheter or the like, which may promote further infection and exacerbate the infection. Therefore, although PDT treatment for septic causative bacteria is even debated, it is unrealistic and has not been studied. Moreover, even though PDT can be a bactericidal technique, it is ineffective for the above-mentioned hypercytokinemia.
- 5-ALA is known as an intermediate of the tetrapyrrole biosynthetic pathway widely present in animals, plants and fungi, and is usually biosynthesized from succinyl CoA and glycine by 5-aminolevulinic acid synthase.
- Photodynamic therapy or photodynamic therapy (hereinafter also referred to as “ALA-PDT”) using 5-ALA has been developed and has attracted attention as a treatment method that is low in invasiveness and maintains QOL. Tumor diagnosis and treatment agents using the above have been reported.
- 5-ALA is also known to be useful as an agent for preventing or improving adult diseases, cancer and male infertility (see, for example, Patent Documents 4 to 6).
- Patent No. 2731032 JP 2006-124372 A Special table 2002-512205 WO2010 / 050179 JP2011-167553A WO2009 / 139156
- An object of the present invention is to provide a prophylactic and / or therapeutic agent for sepsis useful for the prevention and treatment of sepsis.
- the present inventors have scrutinized a huge amount of data such as the pathophysiology, severity, course, prognosis, clinical laboratory values, results of various treatment methods of sepsis patients, and further comprehensively followed past clinical reports, The conclusion was that the amount of cytokines in the blood was the most important for the pathology in Japanese patients, and screening of compounds that suppress inflammatory cytokines was initiated. It was discovered that there is a sex cytokine inhibitory effect. It is known that 5-ALA can be sterilized by PDT by light irradiation as described in the background art above, but the present invention does not require light irradiation.
- 5-ALA has been known as a health food having various health promotion effects, it has never been expected to have a surprising effect of suppressing inflammatory cytokines, which are causative agents of hypercytokinemia. It was. This is clearly a mechanism that is clearly different from the antioxidant effect and immunostimulatory reaction of 5-ALA that we have already found, and as already mentioned, it is high for various antibiotics. Since there is no example of overcoming cytokineemia, it cannot be explained by simple antibacterial action in the first place. The mechanism by which 5-ALA suppresses inflammatory cytokines needs to be awaited for future research.
- the present inventors have further investigated various methods regarding administration methods, combinations with drugs for secondary injury caused by hypercytokinemia, dosages, etc., and sepsis containing 5-ALA and iron as active ingredients. As a result, the present inventors have finally completed the present invention.
- the present invention (1) A prophylactic and / or therapeutic agent for sepsis containing a compound represented by the following formula (I) or a salt thereof,
- R 1 represents a hydrogen atom or an acyl group
- R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).
- R 1 and R 2 are hydrogen atoms, the preventive and / or therapeutic agent for sepsis according to (1), (3) The agent for preventing and / or treating sepsis according to (1) or (2), further comprising one or more metal-containing compounds, (4) Prevention of sepsis according to (3), wherein the metal-containing compound is an iron compound, a magnesium compound, a zinc compound, a nickel compound, a vanadium compound, a copper compound, a chromium compound, a molybdenum compound or a cobalt compound.
- the metal-containing compound is an iron compound, a magnesium compound, a zinc compound, a nickel compound, a vanadium compound, a copper compound, a chromium compound, a molybdenum compound or a cobalt compound.
- the iron compound is ferric chloride, iron sesquioxide, iron sulfate, ferrous pyrophosphate, ferrous citrate, sodium iron citrate, sodium ferrous citrate, ammonium iron citrate, pyrophosphoric acid Ferric, iron lactate, ferrous gluconate, sodium diethylenetriaminepentaacetate, ammonium diethylenetriaminepentaacetate, sodium ethylenediaminetetraacetate, ammonium ethylenediaminetetraacetate, sodium dicarboxymethylglutamate, sodium ammonium dicarboxymethylglutamate , Ferrous fumarate, iron acetate, iron oxalate, ferrous succinate, sodium iron citrate, heme iron, dextran iron, triethylenetetraamine iron, lactoferrin iron, transferrin iron, iron chlorophyll
- the present invention also relates to (9) a method for preventing and / or treating sepsis characterized by administering a compound represented by the above formula (I) or a salt thereof to a subject, and (10) the above (1) to (
- the present invention relates to a method for preventing and / or treating sepsis, which comprises administering the agent for preventing and / or treating sepsis according to any one of 8) to a subject.
- R 1 and R 2 are hydrogen atoms, or the above method characterized in that it contains one or more metal-containing compounds.
- the metal-containing compound is an iron compound, a magnesium compound, a zinc compound, a nickel compound, a vanadium compound, a copper compound, a chromium compound, a molybdenum compound, or a cobalt compound, or the metal-containing compound is an iron compound.
- iron compound is ferric chloride, iron sesquioxide, iron sulfate, ferrous pyrophosphate, ferrous citrate, sodium iron citrate, sodium ferrous citrate , Ammonium iron citrate, ferric pyrophosphate, iron lactate, ferrous gluconate, sodium diethylenetriaminepentaacetate, iron diethylenetriaminepentaacetate Ammonium, ethylenediaminetetraacetic acid iron sodium, ethylenediaminetetraacetic acid iron ammonium, dicarboxymethyl sodium iron glutamate, dicarboxymethyl iron iron glutamate, ferrous fumarate, iron acetate, iron oxalate, ferrous succinate, citric acid citrate
- iron compounds selected from sodium iron oxide, heme iron, dextran iron, triethylenetetraamine iron, lactoferrin iron, transferrin iron, iron chlorophyllin sodium, ferritin iron, sugar-containing iron oxide, and glycine iron sulfide And the above-de
- the present invention also relates to (11) a compound represented by the above formula (I) or a salt thereof for use in the prevention and / or treatment of sepsis.
- a salt thereof, and one or more kinds of metal-containing compounds or metal-containing compounds are an iron compound, a magnesium compound, a zinc compound, a nickel compound, a vanadium compound, a copper compound, a chromium compound, a molybdenum compound, or a cobalt compound.
- the metal-containing compound is an iron compound
- the iron compound is ferric chloride, iron sesquioxide, iron sulfate, ferrous pyrophosphate, citric acid Ferrous acid, sodium iron citrate, sodium ferrous citrate, ammonium iron citrate, ferric pyrophosphate, iron lactate, ferrous gluconate, diet Sodium tritriaminepentaacetate, ammonium diethylenetriaminepentaacetate, sodium iron ethylenediaminetetraacetate, ammonium irondiaminediaminetetraacetate, sodium iron dicarboxymethylglutamate, ammonium dicarboxymethylglutamate, ferrous fumarate, iron acetate, iron oxalate , Ferrous succinate, sodium iron citrate succinate, heme iron, dextran iron, triethylenetetraamine iron, lactoferrin iron, transferrin iron, iron chlorophyllin sodium, ferritin iron, sugar-containing iron oxide, and glycine iron
- the present invention also relates to a kit for preventing and / or treating sepsis comprising (12) a) a compound represented by the above formula (I) or a salt thereof; b) a metal-containing compound.
- the present invention also provides a method for preventing and / or preventing sepsis, characterized by administering (13) a) a compound represented by the above formula (I) or a salt thereof; b) a metal-containing compound; It relates to a method of treatment.
- the present invention also provides (14) a) prophylactic agent and / or therapeutic agent comprising: a sepsis preventive agent and / or therapeutic agent according to any one of (1) to (8); b) a sepsis prophylactic agent / therapeutic agent / concomitant agent; A combination of (15) The present invention relates to a combination of a prophylactic agent and / or a therapeutic agent comprising a) a compound represented by the above formula (I) or a salt thereof; b) a metal-containing compound; c) a prophylactic agent / therapeutic agent / concomitant agent for sepsis.
- the present invention relates to (16) a) the use of a compound represented by the above formula (I) or a salt thereof in the manufacture of a prophylactic and / or therapeutic agent for sepsis.
- IL-6 and / or IL-8 production inhibitors containing ALAs, or ALAs and metal-containing compounds, ALAs, or ALAs and metal-containing compounds.
- a method for inhibiting IL-6 and / or IL-8 production, ALAs for use in inhibiting IL-6 and / or IL-8 production, or ALAs and metal-containing compounds A kit for suppressing production of IL-6 and / or IL-8 containing ALAs and a metal-containing compound, or administering an ALA and a metal-containing compound to a subject simultaneously or before and after IL-6 and / or IL-8 production suppression method, and a prophylactic agent and / or treatment comprising the IL-6 and / or IL-8 production inhibitor and a sepsis preventive agent / therapeutic agent / concomitant agent Combination of drugs and ALA Combinations of prophylactic and / or therapeutic agents including genus-containing compounds and sepsis preventive, therapeutic, and concomitant agents,
- the sepsis preventive agent and / or therapeutic agent comprising the ALA of the present invention as an active ingredient has an excellent therapeutic effect and preventive effect on sepsis. Further, when used in combination with existing sepsis therapeutic agents, it has the effect of increasing the efficacy of hypercytokinemia treatments that have not been reached or reducing the dose of existing sepsis therapeutic agents with strong side effects. It is considered that the preventive agent and / or therapeutic agent for sepsis of the present invention has a completely different mechanism from the existing therapeutic agent for sepsis.
- the prophylactic and / or therapeutic agent for sepsis of the present invention is not particularly limited as long as it contains the compound represented by the above formula (I) or a salt thereof (ALA) as an active ingredient, but in addition to ALAs Metal-containing compounds such as iron compounds can also be contained. Furthermore, those that can be used for suppressing production of IL-6 and / or IL-8 are preferred.
- the prophylactic and / or therapeutic agent for sepsis of the present invention can also be used as pharmaceuticals, quasi drugs, foods and drinks, feeds, feeds, and pet foods.
- the method for preventing and / or treating sepsis according to the present invention comprises administering the above-described preventive and / or therapeutic agent for sepsis according to the present invention to subjects such as livestock, poultry, and pets in addition to humans.
- a prophylactic and / or therapeutic agent for sepsis that does not contain a metal-containing compound such as an iron compound and has an ALA as a single active ingredient is a subject that separately takes an iron compound, This is particularly effective for subjects with high concentrations of iron compounds and the like in the body.
- the kit for preventing and / or treating sepsis of the present invention is not particularly limited as long as it is a kit that individually contains ALAs and a metal-containing compound such as an iron compound as active ingredients. Those that can be used for inhibiting IL-8 production are preferred.
- the method for preventing and / or treating sepsis according to the present invention using the kit for preventing and / or treating sepsis according to the present invention is a method for preventing or / treating sepsis according to the present invention by simultaneously or simultaneously with ALAs and metal-containing compounds such as iron compounds. In addition, it is administered to subjects such as livestock, poultry and pets.
- the combination of the preventive agent and / or therapeutic agent of the present invention includes a combination of the above-mentioned sepsis preventive agent and / or therapeutic agent of the present invention and a sepsis preventive agent / therapeutic agent / concomitant agent, ALAs Is not particularly limited as long as it is a combination of a metal-containing compound such as an iron compound and a prophylactic agent / therapeutic agent / concomitant agent for sepsis, and it is possible to prevent and prevent sepsis by administering a combination of these prophylactic and / or therapeutic agents. / Or can be treated. Each formulation (component) of these combinations can be administered simultaneously or separately.
- the present invention further relates to ALAs for use in the prevention and / or treatment of sepsis, ALAs for use in the prevention and / or treatment of sepsis, and metal-containing compounds such as iron compounds.
- the present invention also relates to the use of ALAs in the production of a prophylactic and / or therapeutic agent for sepsis, and the use of ALAs and a metal-containing compound such as an iron compound in the production of a prophylactic and / or therapeutic agent for sepsis.
- ALAs for use in the prevention and / or treatment of sepsis ALAs for use in the prevention and / or treatment of sepsis
- metal-containing compounds such as iron compounds.
- 5-ALA is one of the amino acids also called ⁇ -aminolevulinic acid.
- R 1 in the formula (I) is a hydrogen atom or an acyl group
- R 2 in the formula (I) is a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group
- compounds other than 5-ALA, which is an aralkyl group can be mentioned.
- alkyl group in the formula (I) examples include linear or branched groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl groups. Mention may be made of alkyl groups having 1 to 8 carbon atoms.
- a cycloalkyl group having 3 to 8 carbon atoms in which a saturated or partially unsaturated bond may exist specifically, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, Examples include cyclooctyl, cyclododecyl, 1-cyclohexenyl and the like.
- the aryl part has the same meaning as the following aryl group
- the alkyl part has the same meaning as the above alkyl group.
- aralkyl having 7 to 15 carbon atoms specifically benzyl, phenethyl , Phenylpropyl, phenylbutyl, benzhydryl, trityl, naphthylmethyl, naphthylethyl and the like.
- aryl group in the formula (I) examples include aryl having 6 to 14 carbon atoms, specifically, phenyl, naphthyl, anthryl, phenanthryl and the like.
- the acyl group in the formula (I) is a linear or branched alkanoyl group having 1 to 8 carbon atoms, specifically formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl. , Benzylcarbonyl and the like, or an aroyl group having 7 to 14 carbon atoms, specifically, benzoyl, 1-naphthoyl, 2-naphthoyl and the like.
- Examples of ALA derivatives used in the present invention include compounds in which the amino group of ALA is acylated and the carboxyl group is esterified. Compounds in which the acyl group is formyl, acetyl, propionyl, butyryl, etc., and compounds in which the ester group is methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, etc.
- formyl and methyl ester are preferred, and formyl and methyl ester, acetyl And combinations of methyl ester, propionyl and methyl ester, butyryl and methyl ester, formyl and ethyl ester groups, acetyl and ethyl ester, propionyl and ethyl ester, butyryl and ethyl ester, and the like.
- Pharmacologically acceptable salts of ALA or ALA derivatives include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts and the like.
- acid addition salts include hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, and other inorganic acid salts, formate, acetate, propionate, toluenesulfonic acid Salt, succinate, oxalate, lactate, tartrate, glycolate, methanesulfonate, butyrate, valerate, citrate, fumarate, maleate, malate, etc. Mention may be made of organic acid addition salts.
- Examples of the metal salt include alkali metal salts such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium and calcium salt, and metal salts such as aluminum and zinc.
- Examples of ammonium salts include ammonium salts and alkylammonium salts such as tetramethylammonium salts.
- Examples of the organic amine salt include triethylamine salts, piperidine salts, morpholine salts, toluidine salts and the like.
- ALA or ALA derivatives can be produced by any method of chemical synthesis, production by microorganisms, and production by enzymes.
- an acyl group in an amino group of an ALA derivative, an ester group in a carboxyl group, or the like can be produced by acylation of an amino group, esterification of a carboxyl group, or the like by a conventional chemical synthesis method.
- a salt of ALA or ALA derivative represented by formula (I) when it is desired to obtain a salt of ALA or ALA derivative represented by formula (I), when the compound represented by formula (I) is obtained in the form of a salt, it may be purified as it is, or when it is obtained in a free form. Then, it may be dissolved or suspended in a suitable organic solvent, and an acid or base may be added to form a salt by a conventional method.
- ALAs may exist in the form of adducts with water or various solvents, and these adducts can also be used for the prophylactic and / or therapeutic agents for sepsis of the present invention.
- ALAs that can be used for the prophylactic and / or therapeutic agent for sepsis of the present invention
- any one of ALA or ALA derivatives or their salts can be used alone, or two or more can be used in appropriate combination.
- ALA and ALA derivatives or salts thereof ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester and pentyl ester, and hydrochlorides, phosphates, and sulfuric acids thereof are desirable.
- the most preferable compound include ALA hydrochloride and ALA phosphate.
- the prophylactic and / or therapeutic agent for sepsis of the present invention can contain a metal-containing compound in combination with ALAs.
- the metal-containing compound can be used in a range that does not cause hyperplasia.
- the metal-containing compound is used in a molar ratio of 1: 0.01 to 1:10, preferably 1: 0.1, relative to ALAs. To 1: 5, more preferably 1: 0.2 to 1: 2.
- the metal-containing compound examples include iron compounds, magnesium compounds, zinc compounds, nickel compounds, vanadium compounds, cobalt compounds, copper compounds, chromium compounds, and molybdenum compounds.
- an iron compound, a magnesium compound, and a zinc compound are preferable, and an iron compound is particularly preferable.
- These metal-containing compounds mean compounds having the metal in the molecule. There is no particular limitation as long as the effect of the present invention is not adversely affected.
- iron compounds having iron in the molecule include ferrous citrate, sodium iron citrate, ammonium iron citrate, ferric pyrophosphate, heme iron, dextran iron, iron lactate, ferrous gluconate, Sodium diethylenetriaminepentaacetate, ammonium diethylenetriaminepentaacetate, sodium ethylenediaminetetraacetate, ammonium ethylenediaminepentaacetate, triethylenetetraamineiron, sodium iron dicarboxymethylglutamate, ammonium ammonium dicarboxymethylglutamate, iron lactoferrin, iron transferrin , Ferric chloride, iron sesquioxide, iron chlorophyllin sodium, ferritin iron, ferrous fumarate, ferrous pyrophosphate, sugar-containing iron oxide, iron acetate, iron oxalate, ferrous succinate, citric succinate Acid iron Potassium, iron sulfate can be exemplified sulfide glycine iron.
- ferric chloride
- Magnesium compounds having magnesium in the molecule include magnesium citrate, magnesium benzoate, magnesium acetate, magnesium oxide, magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium sulfate, magnesium silicate, magnesium nitrate, diethylenetriamine magnesium pentaacetate Ammonium, ethylenediaminetetraacetic acid magnesium disodium, and magnesium protoporphyrin are preferred.
- zinc chloride zinc oxide, zinc nitrate, zinc carbonate, zinc sulfate, diethylenetriaminepentaacetic acid zinc diammonium, ethylenediaminetetraacetic acid zinc disodium, zinc protoporphyrin, and zinc-containing yeast are preferable.
- metal-containing compounds may be used alone or in combination of two or more, and can be administered simultaneously or separately with ALAs.
- the dosage form and administration method may be the same as those of ALAs, or may be used separately.
- a composition containing the ALA and the metal-containing compound each alone or simultaneously Can be administered.
- a composition containing the ALA and the metal-containing compound each alone or simultaneously Can be administered.
- a composition containing the ALA and the metal-containing compound each alone or simultaneously Can be administered.
- ALA and a metal-containing compound such as an iron compound When administered alone, it is preferable to administer at the same time.
- administration of ALA and a metal-containing compound such as an iron compound has an additive effect, preferably a synergistic effect. It is preferable to administer such that
- agent for preventing and / or treating sepsis according to the present invention and the kit for preventing and / or treating sepsis according to the present invention are used in combination with an existing agent for preventing or treating sepsis (preventive agent / therapeutic agent in combination).
- Agent that is, a preventive agent and / or a therapeutic agent and / or a concomitant agent can be used in combination.
- preventive, therapeutic, and concomitant agents for sepsis include penicillin, ⁇ -lactam, cephem, carbapenem, penem, lincomycin, monobactam, tetracycline, chloramphenicol, fosfomycin , New quinolones, fluoroquinolones, aminoglycosides, glycopeptides, linezolids and any other drugs that may be administered during the treatment of sepsis, such as infusions, bicarbonate, vasoconstrictors, thrombus Examples include anti-dissolving agents, cardiotonic agents, ulcer-preventing agents, steroids, activated protein C, blood products, and immunomodulators such as arginine, alginic acid, and omega-3.
- sepsis preventive, therapeutic, and concomitant drugs and the therapeutic effects of 5-ALA on sepsis are considered to be fundamentally different, so the significance of the combination is significant, additive, and sometimes synergistic The effect can be expected.
- These sepsis preventive, therapeutic, and concomitant agents may be used alone or in admixture of two or more.
- These prophylactic / therapeutic / conjunctive agents for sepsis can be administered simultaneously or separately with the prophylactic and / or therapeutic agent for sepsis of the present invention.
- the dosage form and administration method may be the same as the prophylactic and / or therapeutic agent for sepsis of the present invention, or may be used separately.
- ALAs can be administered alone as they are, but other components such as other medicinal ingredients and nutrients can be added as necessary, and it is usually desirable to prepare various pharmaceutical preparations.
- a pharmaceutical preparation can be produced by mixing an active ingredient with one or more pharmacologically acceptable carriers and by a conventional method of pharmaceutics.
- carriers that can be incorporated into the ALAs organic or inorganic solid or liquid suitable for consumption, usually inert, pharmaceutically acceptable carrier materials are used. Specific examples include carriers such as crystalline cellulose, gelatin, lactose, starch, magnesium stearate, talc, vegetable or animal fat and oil, gum, polyalkylene glycol and the like.
- the routes include oral administration including sublingual administration, nasal administration, inhalation administration, intravenous administration including infusion, transdermal administration such as cataplasms, suppositories, or nasogastric tube, nasal intestinal tract, gastric leak And parenteral administration such as administration by forced enteral nutrition using a tube or enteric tube.
- Agents for each component of the prophylactic and / or therapeutic agent for sepsis of the present invention, each component of the kit for preventing and / or treating sepsis of the present invention, and the combination of the prophylactic and / or therapeutic agent of the present invention The type can be appropriately determined depending on the administration route, but is an injection, nasal drop, instillation, tablet, capsule, fine granule, scattered, liquid, syrup, etc. And suppositories.
- Each component of the prophylactic and / or therapeutic agent for sepsis according to the present invention and the kit for preventing and / or treating sepsis according to the present invention can be in the form of a tablet or capsule supplement in addition to pharmaceutical use. .
- a disintegrating tablet form that rapidly disintegrates in the mouth and a liquid form suitable for nasogastric tube administration are preferable.
- These preparations can be produced according to a conventional method using a solvent, a dispersant, a bulking agent, an excipient and the like as appropriate.
- a pharmacologically acceptable carrier and excipient as necessary Add agents, diluents, additives, disintegrants, binders, coatings, lubricants, lubricants, lubricants, flavors, sweeteners, solubilizers, solvents, gelling agents, nutrients, etc.
- an injection may be produced according to a conventional method by adding water, physiological saline, vegetable oil, solubilizer, preservative and the like, and tablets may be produced by, for example, lactose, starch, magnesium stearate, hydroxypropyl cellulose, polyvinyl
- Various additives such as alcohol, surfactant, glycerin and the like may be mixed and manufactured according to a conventional method, and an inhalant may be manufactured according to a conventional method by adding, for example, lactose.
- the agent for preventing and / or treating sepsis according to the present invention and the kit for preventing and / or treating sepsis according to the present invention can be used in veterinary fields such as livestock, poultry and pets in addition to humans.
- the amount, frequency, and duration of administration of such prophylactic and / or therapeutic agents vary depending on the age, weight, symptoms, etc. of the septic patient when the subject is a human, but the dosage of ALAs contained in the preparation is molar.
- the total number of ALAs in terms of number is usually 1 mg to 3000 mg, preferably 3 mg to 1000 mg, more preferably 10 mg to 700 mg per adult, in terms of ALA / hydrochloride.
- the administration time is not particularly selected, but it is preferable to administer once a day or multiple times when the dose is large.
- the number of days of ingestion varies depending on the symptoms, but it is desirable to continue ingestion for 3 to 4 days after symptom relief.
- the prophylactic and / or therapeutic agent for sepsis according to the present invention can be advantageously used in the medical field.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)下記式(I)で示される化合物又はその塩を含有する敗血症の予防剤及び/又は治療剤や、
(3)さらに、一種又は二種以上の金属含有化合物を含むことを特徴とする前記(1)又は(2)記載の敗血症の予防剤及び/又は治療剤や、
(4)金属含有化合物が、鉄化合物、マグネシウム化合物、亜鉛化合物、ニッケル化合物、バナジウム化合物、銅化合物、クロム化合物、モリブデン化合物又はコバルト化合物であることを特徴とする前記(3)記載の敗血症の予防剤及び/又は治療剤や、
(5)金属含有化合物が、鉄化合物であることを特徴とする前記(4)記載の敗血症の予防剤及び/又は治療剤や、
(6)鉄化合物が、塩化第二鉄、三二酸化鉄、硫酸鉄、ピロリン酸第一鉄、クエン酸第一鉄、クエン酸鉄ナトリウム、クエン酸第一鉄ナトリウム、クエン酸鉄アンモニウム、ピロリン酸第二鉄、乳酸鉄、グルコン酸第一鉄、ジエチレントリアミン五酢酸鉄ナトリウム、ジエチレントリアミン五酢酸鉄アンモニウム、エチレンジアミン四酢酸鉄ナトリウム、エチレンジアミン四酢酸鉄アンモニウム、ジカルボキシメチルグルタミン酸鉄ナトリウム、ジカルボキシメチルグルタミン酸鉄アンモニウム、フマル酸第一鉄、酢酸鉄、シュウ酸鉄、コハク酸第一鉄、コハク酸クエン酸鉄ナトリウム、ヘム鉄、デキストラン鉄、トリエチレンテトラアミン鉄、ラクトフェリン鉄、トランスフェリン鉄、鉄クロロフィリンナトリウム、フェリチン鉄、含糖酸化鉄、及び硫化グリシン鉄から選ばれる1種又は2種以上の鉄化合物であることを特徴とする前記(5)記載の敗血症の予防剤及び/又は治療剤や、
(7)鉄化合物が、クエン酸第一鉄ナトリウムであることを特徴とする前記(6)記載の敗血症の予防剤及び/又は治療剤や、
(8)IL-6及び/又はIL-8の産生抑制のために使用する前記(1)~(7)のいずれか記載の敗血症の予防剤及び/又は治療剤、
に関する。
他の(9)の態様として、R1及びR2が、水素原子であることを特徴とする上記方法や、さらに、一種又は二種以上の金属含有化合物を含むことを特徴とする上記方法や、金属含有化合物が、鉄化合物、マグネシウム化合物、亜鉛化合物、ニッケル化合物、バナジウム化合物、銅化合物、クロム化合物、モリブデン化合物又はコバルト化合物であることを特徴とする上記方法や、金属含有化合物が、鉄化合物であることを特徴とする上記方法や、鉄化合物が、塩化第二鉄、三二酸化鉄、硫酸鉄、ピロリン酸第一鉄、クエン酸第一鉄、クエン酸鉄ナトリウム、クエン酸第一鉄ナトリウム、クエン酸鉄アンモニウム、ピロリン酸第二鉄、乳酸鉄、グルコン酸第一鉄、ジエチレントリアミン五酢酸鉄ナトリウム、ジエチレントリアミン五酢酸鉄アンモニウム、エチレンジアミン四酢酸鉄ナトリウム、エチレンジアミン四酢酸鉄アンモニウム、ジカルボキシメチルグルタミン酸鉄ナトリウム、ジカルボキシメチルグルタミン酸鉄アンモニウム、フマル酸第一鉄、酢酸鉄、シュウ酸鉄、コハク酸第一鉄、コハク酸クエン酸鉄ナトリウム、ヘム鉄、デキストラン鉄、トリエチレンテトラアミン鉄、ラクトフェリン鉄、トランスフェリン鉄、鉄クロロフィリンナトリウム、フェリチン鉄、含糖酸化鉄、及び硫化グリシン鉄から選ばれる1種又は2種以上の鉄化合物であることを特徴とする上記方法や、鉄化合物が、クエン酸第一鉄ナトリウムであることを特徴とする上記方法を挙げることができる。
他の(11)の態様として、敗血症の予防及び/又は治療に用いられるための5-ALA又はその塩や、敗血症の予防及び/又は治療に用いられるための上記式(I)で示される化合物又はその塩,及び、一種又は二種以上の金属含有化合物や、金属含有化合物が、鉄化合物、マグネシウム化合物、亜鉛化合物、ニッケル化合物、バナジウム化合物、銅化合物、クロム化合物、モリブデン化合物又はコバルト化合物であることを特徴とする上記発明や、金属含有化合物が、鉄化合物であることを特徴とする上記発明や、鉄化合物が、塩化第二鉄、三二酸化鉄、硫酸鉄、ピロリン酸第一鉄、クエン酸第一鉄、クエン酸鉄ナトリウム、クエン酸第一鉄ナトリウム、クエン酸鉄アンモニウム、ピロリン酸第二鉄、乳酸鉄、グルコン酸第一鉄、ジエチレントリアミン五酢酸鉄ナトリウム、ジエチレントリアミン五酢酸鉄アンモニウム、エチレンジアミン四酢酸鉄ナトリウム、エチレンジアミン四酢酸鉄アンモニウム、ジカルボキシメチルグルタミン酸鉄ナトリウム、ジカルボキシメチルグルタミン酸鉄アンモニウム、フマル酸第一鉄、酢酸鉄、シュウ酸鉄、コハク酸第一鉄、コハク酸クエン酸鉄ナトリウム、ヘム鉄、デキストラン鉄、トリエチレンテトラアミン鉄、ラクトフェリン鉄、トランスフェリン鉄、鉄クロロフィリンナトリウム、フェリチン鉄、含糖酸化鉄、及び硫化グリシン鉄から選ばれる1種又は2種以上の鉄化合物であることを特徴とする上記発明や、鉄化合物が、クエン酸第一鉄ナトリウムであることを特徴とする上記発明を挙げることができる。
(14)a)前記(1)~(8)のいずれか記載の敗血症の予防剤及び/又は治療剤;b)敗血症の予防剤・治療剤・併用剤;を含む予防薬剤及び/又は治療薬剤の組合せや、
(15)a)上記式(I)で示される化合物又はその塩;b)金属含有化合物;c)敗血症の予防剤・治療剤・併用剤;を含む予防薬剤及び/又は治療薬剤の組合せに関する。
ヒト肺動脈血管内皮細胞(5×105 cells/ well, n=3wells)を用い、LPS、および5-ALA添加の有無で次の4群に分けた。
(1)無刺激でのコントロール(図中:コントロール)
(2)5-ALA(100μM)を添加し3時間混合培養(図中:+ALA)
(3)LPS(1μg/mL) を添加し3時間混合培養(図中:+LPS)
(4)5-ALA(100μM)とLPS(1μg/mL)を添加し3時間混合培養(図中:+ALA,LPS)
5-ALAを添加した群には、モル比で5-ALA:クエン酸第一鉄ナトリウム=1: 0.5の割合でクエン酸第一鉄ナトリウムを添加した。
その結果、ヒト肺動脈血管内皮細胞をLPSで刺激し、炎症性サイトカインの分泌を促進させ、敗血症を模したモデルにおいて、5-ALAとクエン酸第一鉄ナトリウムを添加し混合培養することで、炎症性サイトカインであるIL-6、IL-8産生の抑制がみられることを確認した。(n=3,図1、2:+ALA, LPS)
Claims (16)
- R1及びR2が、水素原子であることを特徴とする請求項1記載の敗血症の予防剤及び/又は治療剤。
- さらに、一種又は二種以上の金属含有化合物を含むことを特徴とする請求項1又は2記載の敗血症の予防剤及び/又は治療剤。
- 金属含有化合物が、鉄化合物、マグネシウム化合物、亜鉛化合物、ニッケル化合物、バナジウム化合物、銅化合物、クロム化合物、モリブデン化合物又はコバルト化合物であることを特徴とする請求項3記載の敗血症の予防剤及び/又は治療剤。
- 金属含有化合物が、鉄化合物であることを特徴とする請求項4記載の敗血症の予防剤及び/又は治療剤。
- 鉄化合物が、塩化第二鉄、三二酸化鉄、硫酸鉄、ピロリン酸第一鉄、クエン酸第一鉄、クエン酸鉄ナトリウム、クエン酸第一鉄ナトリウム、クエン酸鉄アンモニウム、ピロリン酸第二鉄、乳酸鉄、グルコン酸第一鉄、ジエチレントリアミン五酢酸鉄ナトリウム、ジエチレントリアミン五酢酸鉄アンモニウム、エチレンジアミン四酢酸鉄ナトリウム、エチレンジアミン四酢酸鉄アンモニウム、ジカルボキシメチルグルタミン酸鉄ナトリウム、ジカルボキシメチルグルタミン酸鉄アンモニウム、フマル酸第一鉄、酢酸鉄、シュウ酸鉄、コハク酸第一鉄、コハク酸クエン酸鉄ナトリウム、ヘム鉄、デキストラン鉄、トリエチレンテトラアミン鉄、ラクトフェリン鉄、トランスフェリン鉄、鉄クロロフィリンナトリウム、フェリチン鉄、含糖酸化鉄、及び硫化グリシン鉄から選ばれる1種又は2種以上の鉄化合物であることを特徴とする請求項5記載の敗血症の予防剤及び/又は治療剤。
- 鉄化合物が、クエン酸第一鉄ナトリウムであることを特徴とする請求項6記載の敗血症の予防剤及び/又は治療剤。
- IL-6及び/又はIL-8の産生抑制のために使用する請求項1~7のいずれか記載の敗血症の予防剤及び/又は治療剤。
- 請求項1~8のいずれか記載の敗血症の予防剤及び/又は治療剤を対象に投与することを特徴とする敗血症を予防及び/又は治療する方法。
- a)請求項1~8のいずれか記載の敗血症の予防剤及び/又は治療剤;
b)敗血症の予防剤・治療剤・併用剤;
を含む予防薬剤及び/又は治療薬剤の組合せ。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12824258.3A EP2745838B1 (en) | 2011-08-12 | 2012-08-10 | Prophylactic agent and/or therapeutic agent for sepsis |
US14/237,407 US9474770B2 (en) | 2011-08-12 | 2012-08-10 | Prophylactic agent and/or therapeutic agent for sepsis |
JP2013528918A JP6052736B2 (ja) | 2011-08-12 | 2012-08-10 | 敗血症の予防剤及び/又は治療剤 |
CN201280037274.7A CN103747784B (zh) | 2011-08-12 | 2012-08-10 | 败血症的预防剂和/或治疗剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011177203 | 2011-08-12 | ||
JP2011-177203 | 2011-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013024589A1 true WO2013024589A1 (ja) | 2013-02-21 |
Family
ID=47714926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/005125 WO2013024589A1 (ja) | 2011-08-12 | 2012-08-10 | 敗血症の予防剤及び/又は治療剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9474770B2 (ja) |
EP (1) | EP2745838B1 (ja) |
JP (1) | JP6052736B2 (ja) |
CN (1) | CN103747784B (ja) |
WO (1) | WO2013024589A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109608249A (zh) * | 2019-02-02 | 2019-04-12 | 浙江科罗尼生物科技有限公司 | 二价铁供给液体及其应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI571455B (zh) | 2011-12-07 | 2017-02-21 | Sbi Pharmaceuticals Co Ltd | To prevent alcohol from causing discomfort to the human body of the hangover preventive agent and / or therapeutic agent |
EP3168296B1 (en) * | 2014-07-11 | 2020-09-09 | SBI Pharmaceuticals Co., Ltd. | Agent for improving normal development rate of fertilized eggs |
JP7113434B2 (ja) * | 2017-05-31 | 2022-08-05 | Sbiファーマ株式会社 | 過活動膀胱の予防剤または治療剤 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2731032B2 (ja) | 1989-07-28 | 1998-03-25 | クイーンズ ユニバーシティ アット キングストン | 光化学療法による悪性および非悪性病変の検出および治療方法 |
JP2002512205A (ja) | 1998-04-22 | 2002-04-23 | マルティ アレクサンドル | 組織病変部の診断または治療のための溶液 |
WO2006025286A1 (ja) * | 2004-09-02 | 2006-03-09 | Cosmo Oil Co., Ltd. | 健康機能向上剤 |
JP2006124372A (ja) | 2004-09-29 | 2006-05-18 | Cosmo Oil Co Ltd | 腫瘍診断剤 |
WO2009139156A1 (ja) | 2008-05-14 | 2009-11-19 | Sbiアラプロモ株式会社 | 男性不妊治療剤 |
WO2010050179A1 (ja) | 2008-10-27 | 2010-05-06 | Sbiアラプロモ株式会社 | 5-アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とする成人病の予防・改善剤 |
JP2011016753A (ja) | 2009-07-08 | 2011-01-27 | Sbi Alapromo Co Ltd | 5−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤 |
-
2012
- 2012-08-10 WO PCT/JP2012/005125 patent/WO2013024589A1/ja active Application Filing
- 2012-08-10 EP EP12824258.3A patent/EP2745838B1/en active Active
- 2012-08-10 US US14/237,407 patent/US9474770B2/en active Active
- 2012-08-10 JP JP2013528918A patent/JP6052736B2/ja active Active
- 2012-08-10 CN CN201280037274.7A patent/CN103747784B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2731032B2 (ja) | 1989-07-28 | 1998-03-25 | クイーンズ ユニバーシティ アット キングストン | 光化学療法による悪性および非悪性病変の検出および治療方法 |
JP2002512205A (ja) | 1998-04-22 | 2002-04-23 | マルティ アレクサンドル | 組織病変部の診断または治療のための溶液 |
WO2006025286A1 (ja) * | 2004-09-02 | 2006-03-09 | Cosmo Oil Co., Ltd. | 健康機能向上剤 |
JP2006124372A (ja) | 2004-09-29 | 2006-05-18 | Cosmo Oil Co Ltd | 腫瘍診断剤 |
WO2009139156A1 (ja) | 2008-05-14 | 2009-11-19 | Sbiアラプロモ株式会社 | 男性不妊治療剤 |
WO2010050179A1 (ja) | 2008-10-27 | 2010-05-06 | Sbiアラプロモ株式会社 | 5-アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とする成人病の予防・改善剤 |
JP2011016753A (ja) | 2009-07-08 | 2011-01-27 | Sbi Alapromo Co Ltd | 5−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤 |
Non-Patent Citations (6)
Title |
---|
ARCH DERMATOL, vol. 136, September 2000 (2000-09-01), pages 1093 - 1095 |
LOMNITSKI, L. ET AL.: "Effects of antioxidants apocynin and the natural water-soluble antioxidant from spinach on cellular damage induced by lipopolysaccaride in the rat", TOXICOL. PATHOL., vol. 28, no. 4, 2000, pages 580 - 587, XP055141441 * |
MIROCHNITCHENKO, O. ET AL.: "Endotoxemia in transgenic mice overexpressing human glutathione peroxidases", CIRC. RES., vol. 87, no. 4, 2000, pages 289 - 295, XP055141437 * |
RITTER, C. ET AL.: "Treatment with N- acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis", CRIT. CARE MED., vol. 32, no. 2, 2004, pages 342 - 349, XP008172707 * |
See also references of EP2745838A4 |
WILSON, J.X. ET AL.: "Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium", BIOFACTORS, vol. 35, no. 1, 2009, pages 5 - 13, XP055141439 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109608249A (zh) * | 2019-02-02 | 2019-04-12 | 浙江科罗尼生物科技有限公司 | 二价铁供给液体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US9474770B2 (en) | 2016-10-25 |
US20140186464A1 (en) | 2014-07-03 |
CN103747784A (zh) | 2014-04-23 |
JPWO2013024589A1 (ja) | 2015-03-05 |
EP2745838B1 (en) | 2017-07-26 |
EP2745838A1 (en) | 2014-06-25 |
CN103747784B (zh) | 2018-01-30 |
JP6052736B2 (ja) | 2016-12-27 |
EP2745838A4 (en) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5920901B2 (ja) | インフルエンザウイルス感染症の予防・治療剤 | |
JP4754731B2 (ja) | 豚成育促進剤及び豚成育促進方法 | |
JP5582441B2 (ja) | 5−アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬 | |
JP5881721B2 (ja) | 慢性腎臓病の改善・予防剤 | |
JP6051283B2 (ja) | 抗ガン剤の副作用の予防剤及び/又は治療剤 | |
JP6052736B2 (ja) | 敗血症の予防剤及び/又は治療剤 | |
WO2014017046A1 (ja) | 放射線障害の予防及び/又は治療剤 | |
JP5818905B2 (ja) | エリスロポエチン産生促進剤 | |
WO2016163082A1 (ja) | Ala類を含むウイルス感染症予防/治療剤 | |
ES2755303T3 (es) | Composición medicinal para potenciar la síntesis de protoporfirina IX | |
KR20070117534A (ko) | 소화관으로부터의 미량 원소 흡수 장애를 예방 및 치료하는데에 사용하기 위한 영양제 및/또는 약제 | |
TWI590823B (zh) | Cancerous anemia to improve, prevention agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12824258 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012824258 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013528918 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14237407 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |